In this context it is suggested that targeting TGF-β2 may (1) provide potent anti-fibrosis/anti-scarring activity in trabeculectomy (2) mediate effective neuroprotection by blocking extracellular matrix remodeling, and (3) prevent trabecular meshwork alteration, (with 2) and (3) both being central to glaucoma disease pathophysiology. Here, TGFB2 is linked to glaucoma.